NDC 83112-0985-56: Doxycycline Hyclate 100 mg Capsule, 56-count
This is a package of 56 capsules of Doxycycline Hyclate 100 mg Capsule from Health Department, Oklahoma State, first listed with the FDA Sep 1984 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 83112-985-56 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 83112 labeler · 985 product · 56 package
- Listing certified through
- Dec 31, 2027
- Barcode (UPC-A, from the NDC)
- 3 8311298556 5
- FDA record last changed
- Jul 24, 2026
Other active recalls for Doxycycline Hyclate (different manufacturers) — 1 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 1649988
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
RxNorm drug class
This medicine belongs to the Tetracycline-class Drug class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Nov 19, 2026
Clinical
- It’s an antibiotic for many bacterial infections, such as tick-borne illness, chlamydia, respiratory infections and eye infections. It’s also used to prevent malaria and treat anth...
- Most forms are taken by mouth with a full glass of water, and you should stay upright afterward to protect your esophagus. Dairy, antacids and iron can reduce absorption. Follow yo...
- It can make your skin burn much more easily. Limit sun and tanning beds, wear loose protective clothing, and talk to your doctor about other sun protection.
- Why do I need to avoid the sun on doxycycline?
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Doxycycline Hyclate — tap one for details:
Doxycycline Hyclate may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 83112-0985-05 83112-985-05 Main listing | 1 CAPSULE in 1 PACKET | 2023-02-01 | — | Active |
| 83112-0985-28 83112-985-28 | 28 CAPSULE in 1 PACKAGE | 2023-02-01 | — | Active |
| 83112-0985-42 83112-985-42 | 42 CAPSULE in 1 PACKAGE | 2023-02-08 | — | Active |
| 83112-0985-56 You're viewing this | 56 CAPSULE in 1 PACKAGE | 2023-02-08 | — | Active |
| 83112-0985-14 83112-985-14 | 14 CAPSULE in 1 PACKAGE | 1984-09-11 | — | Active |
You're viewing the largest of 5 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 83112-0985-05?
What NDC number is used to bill for this package of Doxycycline Hyclate 100 mg Capsule?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Doxycycline Hyclate 100 mg 00143-9803-05 | Hikma | 500 capsules | $0.112 | AB | Availability likely | — |
| Doxycycline Hyclate 100 mg 00904-0428-04 | Major | 30 capsules | $0.112 | AB | Availability likely | — |
| doxycycline 100 mg 27808-0233-01 | Cranbury | 50 capsules | $0.112 | AB | Availability likely | — |
| Doxycycline Hyclate 100 mg 50268-0278-15 | AvPAK | 50 capsules | $0.112 | AB | Availability likely | — |
| Doxycycline Hyclate 100 mg 53489-0119-02 | Sun | 50 capsules | $0.112 | AB | Availability likely | — |
| Doxycycline Hyclate 100 mg 60687-0513-65 | American | 50 capsules | $0.112 | AB | Availability likely | — |
| doxycycline hyclate 100 mg 62332-0363-50 | Alembic | 50 capsules | $0.112 | AB | Availability likely | — |
| Doxycycline Hyclate 100 mg 69238-1100-02 | Amneal | 50 capsules | $0.112 | AB | Availability likely | — |
| Doxycycline Hyclate 100 mg 27241-0141-08 | Ajanta | 500 capsules | — | — | FDA listed | — |
| Doxycycline Hyclate 100 mg 33342-0386-08 | Macleods | 50 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 43063-0988-20 | PD-Rx | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 43063-0999-06 | PD-Rx | 6 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 46708-0363-50 | Alembic | 50 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 49999-0126-30 | Quality | 30 capsules | — | AB | Discontinued | — |
| doxycycline hyclate 100 mg 50090-5560-01 | A-S | 20 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 50090-5588-00 | A-S | 20 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 50090-7410-01 | A-S | 14 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 50090-7411-01 | A-S | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 51655-0478-20 | Northwind | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 60219-1100-01 | Amneal | 100 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 60760-0721-20 | ST. | 20 capsules | — | AB | Discontinued | — |
| Doxycycline Hyclate 100 mg 61919-0082-20 | DIRECT | 20 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 62135-0985-01 | Chartwell | 100 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 67046-0135-03 | Coupler | 30 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 68071-2761-02 | NuCare | 2 capsules | — | AB | Discontinued | — |
| Doxycycline Hyclate 100 mg 68071-4883-04 | NuCare | 4 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 68071-4950-02 | NuCare | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 68071-5232-04 | NuCare | 4 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 68071-5259-02 | NuCare | 20 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 68788-8588-01 | Preferred | 14 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 68999-0985-05 | Chartwell | 500 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 69434-0017-03 | Zhejiang | 500 capsules | — | — | FDA listed | — |
| Doxycycline Hyclate 100 mg 70518-1248-00 | REMEDYREPACK | 14 capsules | — | AB | FDA listed | — |
| Doxycyclate Hyclate 100 mg 70518-1627-00 | REMEDYREPACK | 30 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 70518-3488-00 | REMEDYREPACK | 20 capsules | — | AB | FDA listed | — |
| Doxycycline hyclate 100 mg 70518-4150-00 | REMEDYREPACK | 14 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 70518-4655-00 | REMEDYREPACK | 10 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 70518-4658-00 | REMEDYREPACK | 6 capsules | — | AB | FDA listed | — |
| Doxycycline hyclate 100 mg 70771-1359-00 | Zydus | 1000 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 71205-0385-14 | Proficient | 14 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 71205-0518-02 | Proficient | 2 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 71335-0861-00 | Bryant | 6 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 71335-1464-00 | Bryant | 6 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 71335-1549-00 | Bryant | 6 capsules | — | AB | FDA listed | — |
| Doxycycline hyclate 100 mg 71335-2086-00 | Bryant | 6 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 71335-2100-00 | Bryant | 6 capsules | — | AB | FDA listed | — |
| Doxycycline 100 mg 72189-0006-20 | Direct_Rx | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 72189-0559-20 | Diirect_rx | 20 capsules | — | AB | FDA listed | — |
| Doxycycline hyclate 100 mg 72578-0055-01 | Viona | 100 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 72789-0277-20 | PD-Rx | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 72789-0298-20 | PD-Rx | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 72789-0369-02 | PD-Rx | 2 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 76420-0044-10 | Asclemed | 10 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 76420-0562-10 | Asclemed | 10 capsules | — | AB | FDA listed | — |
| Doxycycline hyclate 100 mg 76420-0813-00 | Asclemed | 1000 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 80425-0114-02 | Advanced | 30 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 80425-0211-01 | Advanced | 20 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 80425-0280-01 | Advanced | 10 capsules | — | AB | FDA listed | — |
| doxycycline 100 mg 82804-0046-06 | Proficient | 6 capsules | — | AB | FDA listed | — |
| Doxycycline hyclate 100 mg 82804-0179-14 | Proficient | 14 capsules | — | AB | FDA listed | — |
| Doxycycline 100 mg 83112-0233-28 | Health | 28 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mgthis 83112-0985-56 | Health | 56 capsules | — | AB | FDA listed | — |
| Doxycycline hyclate 100 mg 85766-0033-00 | Sportpharm | 1000 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 85766-0052-01 | Sportpharm | 100 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 87441-0029-01 | Unit | 30 capsules | — | AB | FDA listed | — |
| doxycycline hyclate 100 mg 85534-0048-00 | HAWAII | 10 capsules | — | AB | FDA listed | — |
| Doxycycline Hyclate 100 mg 50090-8147-01 | A-S | 20 capsules | — | AB | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
What it looks like
Where does this data come from?
- FDA label on DailyMed · label index refreshed Nov 21, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Doxycycline inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 21, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Health Department, Oklahoma State labeler code 83112
- Doxycycline Hyclate 100 mg Tablet, Film Coated NDC 83112-100-00
- Doxycycline 100 mg Capsule NDC 83112-233-28
- Cefixime 400 mg 400 mg Capsule NDC 83112-400-00
- Amoxicillin 500 mg 500 mg Capsule NDC 83112-500-21
- Azithromycin Dihydrate 500 mg Tablet, Film Coated NDC 83112-501-00
- Banophen Diphenhydramine HCl 25 mg Tablet, Film Coated NDC 83112-555-59
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
⚠️ Warnings ▾
Doxycycline Hyclate 100 mg Warnings Section The use of drugs of the tetracycline class during tooth development (last half of pregnancy, infancy and childhood to the age of 8 years) may cause permanent discoloration of the teeth (yellow-gray-brown). This adverse reaction is more common during long-term use of the drugs, but it has been observed following repeated short-term courses. Enamel hypoplasia has also been reported.
Use doxycycline in pediatric patients 8 years of age or less only when the potential benefits are expected to outweigh the risks in severe or life-threatening conditions (e.g., anthrax, Rocky Mountain spotted fever), particularly when there are no alternative therapies. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including doxycycline, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following the use of antibacterial drugs.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing use of antibacterial drugs not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Severe skin reactions, such as exfoliative dermatitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in patients receiving doxycycline. (See ADVERSE REACTIONS.) If severe skin reactions occur, doxycycline should be discontinued immediately and appropriate therapy should be instituted. Intracranial hypertension (IH, pseudotumor cerebri) has been associated with the use of tetracyclines including doxycycline.
Clinical manifestations of IH include headache, blurred vision, diplopia, and vision loss; papilledema can be found on fundoscopy. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline associated IH. Concomitant use of isotretinoin and doxycycline should be avoided because isotretinoin is also known to cause pseudotumor cerebri.
Although IH typically resolves after discontinuation of treatment, the possibility for permanent visual loss exists. If visual disturbance occurs during treatment, prompt ophthalmologic evaluation is warranted. Since intracranial pressure can remain elevated for weeks after drug cessation patients should be monitored until they stabilize.
All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in fibula growth rate has been observed in prematures given oral tetracycline in doses of 25 mg/kg every 6 hours. This reaction was shown to be reversible when the drug was discontinued.
Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
The antianabolic action of the tetracyclines may cause an increase in BUN. Studies to date indicate that this does not occur with the use of doxycycline in patients wi… [Excerpted — this section continues on DailyMed.]
📄 Package Label / Principal Display Panel ▾
Doxycycline Packaging Doxycycline cards Doxy EPT Doxy 14 count Doxy 20 count Doxy 28 count Doxy PEP Doxy 42 Doxy 56 (Front) Doxy 56 (Back)
Medicare Part D spend CMS · PART D · 2026 (Q1)
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |